Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results

Journal of Hypertension
Luis M RuilopeLuc F Van Gaal

Abstract

Rimonabant, the first selective cannabinoid type 1 (CB1) receptor blocker, has been shown to improve multiple cardiometabolic risk factors in overweight/obese patients. This analysis assessed the impact of rimonabant on blood pressure in the pooled population from four large trials with similar design - the Rimonabant-In-Obesity (RIO) programme. RIO-Europe (n = 1507) and RIO-North America (n = 3040) recruited overweight/obese patients, and RIO-Lipids (n = 1033) and RIO-Diabetes (n = 1045) recruited overweight/obese patients with untreated dyslipidaemia or type 2 diabetes, respectively. At study entry (screening), 37.2% (n = 2463) of patients had hypertension, 71.4% (n = 1757) of whom were taking an antihypertensive treatment. After 1 year of treatment, mean change in systolic blood pressure (SBP) from baseline was -0.8 mmHg for rimonabant 20 mg versus +0.3 mmHg for placebo (P = 0.007); diastolic blood pressure (DBP) decreased by -0.8 versus -0.3 mmHg (P = 0.029) respectively. In the subgroup of patients with high blood pressure at baseline, SBP change was -7.5 mmHg for rimonabant 20 mg versus -4.7 mmHg for placebo (P = 0.005); DBP change was -5.2 versus -3.0 mmHg (P < 0.001). Reductions were more pronounced in patients with dys...Continue Reading

References

Jan 24, 1998·Annals of Internal Medicine·Z HuangG A Colditz
Aug 17, 1999·Journal of Human Hypertension·I S OkosunR S Cooper
Jan 31, 2003·The New England Journal of Medicine·Peter GaedeOluf Pedersen
May 16, 2003·JAMA : the Journal of the American Medical Association·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Aug 5, 2003·The Journal of Clinical Investigation·Daniela CotaUberto Pagotto
Nov 15, 2003·Lancet·Fiona Turnbull, UNKNOWN Blood Pressure Lowering Treatment Trialists' Collaboration
Feb 27, 2004·The American Journal of Clinical Nutrition·Ian JanssenRobert Ross
Apr 8, 2004·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Kevin P Davy, John E Hall
May 3, 2005·The Journal of Clinical Investigation·Douglas Osei-HyiamanGeorge Kunos
Sep 28, 2005·Diabetes·Stefan EngeliJens Jordan
Nov 18, 2005·The New England Journal of Medicine·Jean-Pierre DesprésUNKNOWN Rimonabant in Obesity-Lipids Study Group
Feb 16, 2006·JAMA : the Journal of the American Medical Association·F Xavier Pi-SunyerUNKNOWN RIO-North America Study Group
May 11, 2006·The Journal of Clinical Endocrinology and Metabolism·Isabel MatiasVincenzo Di Marzo
Dec 15, 2006·Nature·Luc F Van GaalChristophe E De Block
Dec 15, 2006·Nature·Jean-Pierre Després, Isabelle Lemieux
Jan 17, 2007·International Journal of Obesity : Journal of the International Association for the Study of Obesity·M CôtéV Di Marzo
Mar 14, 2007·Journal of Hypertension·Jens JordanUNKNOWN European Society of Hypertension Working Group on Obesity

❮ Previous
Next ❯

Citations

Aug 13, 2013·Current Hypertension Reports·Stefan Engeli, Jens Jordan
Nov 4, 2011·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Graziela Z Kalil, William G Haynes
Mar 12, 2009·Journal of Cardiovascular Pharmacology·C Robin Hiley
Jul 9, 2008·Current Opinion in Lipidology·David Jesudason, Gary Wittert
Apr 3, 2012·Acta Physiologica·E KirillyG Bagdy
Aug 2, 2008·Expert Opinion on Pharmacotherapy·Bikash Sharma, David C Henderson
Mar 3, 2009·Expert Opinion on Emerging Drugs·David R Janero, Alexandros Makriyannis
Nov 9, 2011·Neuropharmacology·John C Clapham
Apr 26, 2011·Pharmacology & Therapeutics·John C Clapham, Jonathan R S Arch
Dec 17, 2008·Nutrition Research·Timothy P CarrAndrew W Brown
Aug 30, 2008·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·F AkbasT M Larsen
Jan 8, 2009·The Journal of Clinical Hypertension·Janet B McGillMichael Weber
Dec 17, 2008·Congestive Heart Failure·Partha MukhopadhyayPál Pacher
Oct 16, 2010·Cardiovascular Therapeutics·Ronen Durst, Chaim Lotan
Jan 4, 2013·Diabetes/metabolism Research and Reviews·Vojtěch Hainer, Irena Aldhoon Hainerová
Feb 7, 2012·International Journal of Cardiology·Anna GlubaMaciej Banach
Mar 17, 2009·Best Practice & Research. Clinical Endocrinology & Metabolism·André J Scheen, Nicolas Paquot
May 24, 2008·American Journal of Hypertension·Riccardo SarzaniAlessandro Rappelli
Jun 29, 2011·Journal of Psychopharmacology·Saoirse E O'SullivanDavid A Kendall
Feb 20, 2018·British Journal of Pharmacology·Barbara MalinowskaEberhard Schlicker
May 9, 2008·Journal of Neuroendocrinology·R Sarzani
May 9, 2008·Journal of Neuroendocrinology·G GrassiG Mancia
Aug 20, 2008·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·M A StorrK A Sharkey
Sep 23, 2008·Journal of Hypertension·Josep RedonUNKNOWN Scientific Council of the European Society of Hypertension
Jan 22, 2009·Journal of Hypertension·Markus P SchlaichUNKNOWN Australian and New Zealand Obesity Society
Dec 24, 2010·Journal of Hypertension·Jens JordanUNKNOWN Australian and New Zealand Obesity Society
Aug 8, 2012·International Journal of Obesity : Journal of the International Association for the Study of Obesity·Q GeS M Brichard
May 6, 2010·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Vasilios KotsisGianfranco Parati
Feb 13, 2009·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Stéphanie MigrenneChristophe Magnan
Oct 4, 2012·Journal of Hypertension·Stefan EngeliJens Jordan
Sep 10, 2019·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·Giacomo RossiMatteo Cerquetella

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.